The Immune System – News and Features

The PDC allocates funds to a 7,000 square foot R&D facility in Portland for development and manufacturing of QuantRx lateral flow devices.

The combination of the two approaches will offer an opportunity to develop molecules having disease-modifying therapies for Alzheimer’s disease.

Company’s Phase III program will be the last phase of testing before it seeks full approval for Crohn’s Disease.

Alnylam has taken a worldwide exclusive license to Inex's liposomal delivery formulation technology for the discovery, development, and commercialization of RNAi therapeutics.

The project funding $15M, will occur in Scotland with over 40 new jobs created in the universities, and 50 new jobs projected for the core laboratory.

The Patent Office has issued a "Notice of Intent to Issue a Re-examination Certificate" after re-evaluating PharmaStem's U.S. Patent No. 5,192,553, thus terminating the reexamination proceeding.

UCSF scientists determine that adult stem cells in the mouse brain have a built-in mechanism that allows the cells to participate in the repair of damaged tissue.

Researchers found that the more T-regulatory cells and the fewer T-cell lymphocytes present in the tumors of treated patients, the greater the likelihood the cancer would recur.

St. Jude researchers find that harvesting aggressive stem cells from donated bone marrow could speed rebuilding of the immune system, reduce risk of infection.

Panacea Biotec is to in-license CBL’s stable liquid technology to develop, produce and market a liquid version of pentavalent.